AKB-6548, A NOVEL HYPOXIA-INDUCIBLE FACTOR PROLYL-HYDROXYLASE INHIBITOR (HIF-PHI) FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (ND-CKD)

被引：1
|
作者：
Pergola, Pablo E. [1 ]
Spinowitz, Bruce [2 ]
Haase, Volker H. [3 ]
Hartman, Charlotte S. [4 ]
Farmer, Tasha M. [4 ]
Polu, Krishna R. [4 ]
Maroni, Bradley [4 ]
Shalwitz, Robert [4 ]
机构：
[1] Renal Associates PA, Nephrol, San Antonio, TX USA
[2] 2New York Hosp Queens, Nephrol, Flushing, NY USA
[3] Vanderbilt Univ, Nephrol & Hypertens, Nashville, TN 37235 USA
[4] Akebia Therapeut Inc, Nephrol, Cambridge, MA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷
关键词：
D O I：
10.1093/ndt/gfv138.2
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FO015
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease
    Del Vecchio, Lucia
    Locatelli, Francesco
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (07) : 613 - 621
  • [2] Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
    Kurata, Yu
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (04): : 414 - 422
  • [3] Daprodustat Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of anemia associated with chronic kidney disease
    Gras, J.
    [J]. DRUGS OF THE FUTURE, 2017, 42 (06) : 327 - 333
  • [4] VADADUSTAT Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of anemia secondary to chronic kidney disease
    Cole, P.
    [J]. DRUGS OF THE FUTURE, 2016, 41 (10) : 601 - 606
  • [5] Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia
    Zuk, Anna
    Si, Zhihai
    Loi, Sally
    Bommegowda, Santhosh
    Hoivik, Debie
    Danthi, Sanjay
    Molnar, Gyongyi
    Csizmadia, Vilmos
    Rabinowitz, Michael
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 383 (01): : 11 - 24
  • [6] Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis
    Siliang Zhang
    Jing Guo
    Shuqin Xie
    Jianwei Chen
    Shenrun Yu
    Yuan Yu
    [J]. International Urology and Nephrology, 2021, 53 : 1139 - 1147
  • [7] Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis
    Zhang, Siliang
    Guo, Jing
    Xie, Shuqin
    Chen, Jianwei
    Yu, Shenrun
    Yu, Yuan
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (06) : 1139 - 1147
  • [8] Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKD
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 (01) : 24 - 31
  • [9] ROXADUSTAT Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of Anemia
    Virgili-Lopez, G.
    [J]. DRUGS OF THE FUTURE, 2014, 39 (11) : 783 - 791
  • [10] Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease
    del Balzo, Ughetta
    Signore, Pierre E.
    Walkinshaw, Gail
    Seeley, Todd W.
    Brenner, Mitchell C.
    Wang, Qingjian
    Guo, Guangjie
    Arend, Michael P.
    Flippin, Lee A.
    Chow, F. Aisha
    Gervasi, David C.
    Kjaergaard, Christian H.
    Langsetmo, Ingrid
    Guenzler, Volkmar
    Liu, David Y.
    Klaus, Steve J.
    Lin, Al
    Neff, Thomas B.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2020, 374 (02): : 342 - 353
12345